Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report

Background: Osimertinib is recommended either as the first-line therapy for sensitizing EGFR-mutations (FLAURA trial) or at progression to first-/second-generation EGFR inhibitors in the presence of resistance mutation T790M (AURA 3 study). It can effectively improve the prognosis of patients with N...

Descripción completa

Detalles Bibliográficos
Autores principales: Shujun, Wang, Lili, Lou, Lei, Yang, Feng, Wang, Hefeng, Zhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037232/
https://www.ncbi.nlm.nih.gov/pubmed/35479327
http://dx.doi.org/10.3389/fphar.2022.854277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037232/
https://www.ncbi.nlm.nih.gov/pubmed/35479327
http://dx.doi.org/10.3389/fphar.2022.854277

Ejemplares similares